Compare LCTX & XFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCTX | XFLT |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.4M | 250.4M |
| IPO Year | 1996 | 2017 |
| Metric | LCTX | XFLT |
|---|---|---|
| Price | $1.02 | $16.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 110.9K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 14.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,556,000.00 | N/A |
| Revenue This Year | $4.38 | N/A |
| Revenue Next Year | $10.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $0.88 | $3.02 |
| 52 Week High | $1.99 | $19.63 |
| Indicator | LCTX | XFLT |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 30.85 |
| Support Level | $1.02 | $15.86 |
| Resistance Level | $1.05 | $19.53 |
| Average True Range (ATR) | 0.06 | 0.42 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 72.53 | 27.39 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
XAI Octagon Floating Rate & Alternative Income Trust is a diversified, closed-end management investment company which invests in a dynamically managed portfolio of floating-rate credit instruments and other structured credit investments within the private markets. The Trust's investment objective is to seek attractive total return with an emphasis on income generation across multiple stages of the credit cycle.